MARKET NEWS

Principia Achieves $10 Million in Additional Milestones
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ
Krystal Biotech Announces Positive Interim Results
Importance of Cell Cycle & Cellular Senescence in the Placenta Discovered
Athenex & Xiangxue Life Sciences Announce Preliminary Study Results
Sarepta & Lysogene Announce Exclusive License Agreement

  FEATURED EDITORIAL

  COMPANY PROFILE

Mitsubishi Gas Chemical (MGC) is a leading company in the field of functional chemicals, such as oxygen barrier and absorbing polymers. MGC established the Advanced Business Development Division in 2015 for tackling a variety of today’s problems, and the division created OXYCAPTTM Multilayer Plastic Vial & Syringe to solve some issues of existing primary packaging for injectable drugs. Click here for more.

  EXCLUSIVE ONLINE CONTENT

VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study

VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study

VBI Vaccines Inc. recently announced the last subject has received the last vaccination in the PROTECT Phase 3 study of Sci-B-Vac, the company’s third-generation prophylactic hepatitis B vaccine.

Arcis Biotechnology & Teleflex Sign License Agreement   

Arcis Biotechnology & Teleflex Sign License Agreement  

Arcis Biotechnology recently announced it has signed a technology access agreement with Teleflex Incorporated. Teleflex will harness Arcis’ advanced nucleic acid sample preparation chemistry in the development of a novel technology, which it believes will be disruptive, and is intended to empower clinicians and drive better patient outcomes.

Hovione Increases Production Capacity; One-Site-Shop Expands to Respond to Growing Demands 

Hovione Increases Production Capacity; One-Site-Shop Expands to Respond to Growing Demands 

Hovione recently announced a plan to increase production capacity in oral dosage forms in Portugal to strengthen the integrated offering. New commercial-scale equipment for blending, tableting, and coating will complement existing development small-scale equipment.

A New Generation of Ophthalmic Products With Pylote Eco-Friendly Protection Offers Improved Safety & Comfort for Patients

A New Generation of Ophthalmic Products With Pylote Eco-Friendly Protection Offers Improved Safety & Comfort for Patients

Like all pharmaceuticals, ophthalmic preparations are subject to microbiological contamination. Both ophthalmic solutions used for diagnostic and therapeutic purposes have been found to be contaminated by pathogenic bacteria with reported rates as high as 70%, associated with severe ocular infections such as keratitis and endophthalmitis.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 31 – Analytical Testing
November 7 – Formulation Development